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Two Phase 3 Trials of Dupilumab versus Placebo in Atopic 
Dermatitis
To the Editor: The conclusions of Simpson and 
colleagues (Dec. 15 issue)1 regarding the effec-
tiveness and quality-of-life–enhancing capacity 
of dupilumab in patients with atopic dermatitis 
open new perspectives in the strategies of treat-
ment of allergic diseases, because interleukin-4 
and interleukin-13 are “type 2 inflammatory cyto-
kines that may be important drivers of atopic or 
allergic diseases.” Given the good results in pa-
tients with asthma2 or nasal polyposis,3 we as 
pediatricians look with interest to the possibili-
ties arising from these studies involving adults. 
However, the higher rate of allergic conjunctivitis 
in the dupilumab-treated population than in the 
placebo group in this trial runs against these 
wishes. Although we agree with the authors that 
“further studies on the causes of conjunctivitis 
are warranted,” could these be cases of atopic 
keratoconjunctivitis rather than simple allergic 
conjunctivitis? This condition is often linked to 
atopic dermatitis.4 If so, could it be hypothe-
sized that the blockage of interleukin-4 and inter-
leukin-13 increases the activity of the specific 
ligands involved in atopic keratoconjunctivitis 
(e.g., the OX40 ligand) in the eye, an immuno-
logically privileged area?5 This would limit the 
potential uses of dupilumab in the allergy field.
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The authors reply: In trials of dupilumab in-
volving patients with atopic dermatitis, conjunc-
tivitis occurred more often in patients who had 
severe atopic dermatitis or coexisting allergic 
conjunctivitis (>25% of the enrolled patients). More 
than 90% of the adverse events of conjunctivitis 
were mild or moderate in severity, and more than 
75% resolved or were resolving during study 
treatment. In the SOLO trials, 1 of 920 patients 
who were treated with dupilumab discontinued 
study treatment because of conjunctivitis. Dupilu-
mab was not associated with a higher rate of ad-
verse events of conjunctivitis than placebo in trials 
involving patients with asthma or nasal polypo-
sis,1,2 which suggests an atopic dermatitis–specific 
mechanism, not an inherent effect of dupilumab.
The cause is unclear. Not all cases were diag-
nosed by ophthalmologists. Findings did not typi-
cally suggest atopic keratoconjunctivitis. Two 
clinical phenotypes were noted: blepharoconjunc-
tivitis that was consistent with atopic dermatitis 
in the eyelids and periorbital area, and conjunc-
tivitis with limbal accentuation. The incidence of 
atopic keratoconjunctivitis was less than 0.5% 
across all groups and was not higher in the dupi-
lumab group than in the placebo group. Although 
the cornea is immune-privileged, the rest of the 
ocular surface, eyelids, and periorbital skin are not.
There is an inverse relationship between se-
rum concentrations of dupilumab and conjuncti-
vitis, which suggests that local undertreatment, 
possibly due to higher target burden or lower 
tissue distribution, may play a role. In our trials 
and others,1,2 dupilumab effectively inhibited the 
inflammation of type 2 helper T (Th2) cells in 
patients with atopic dermatitis, asthma, or nasal 
polyposis. Similar Th2-cell inflammatory path-
ways are involved in atopic keratoconjunctivitis.
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Short-Term versus Long-Term Blood Storage
To the Editor: In the Informing Fresh versus 
Old Red Cell Management (INFORM) study, 
Heddle et al. (Nov. 17 issue)1 suggest that the 
debate over red-cell storage and outcome after 
transfusion is now closed. According to the ac-
companying editorial,2 there may no longer be an 
issue regarding the freshness of red cells for 
transfusion. Although we admire the quality of 
all five recent, large cited studies on this topic2 
(which have covered such diverse topics as the 
relationship between the age of blood and type of 
processing to patients’ outcomes), we consider 
this conclusion to be questionable.
Previous studies have stressed the safety and 
survival benefit of a restrictive policy versus a 
liberal policy for red-cell transfusion, which sug-
gests a downside to such transfusion.3 Red-cell 
storage lesions may explain this observation. 
Stored red cells have both reversible and irre-
versible lesions; the latter occur from the second 
week onward.4 However, recent studies have com-
pared red cells that were stored for 7 to 10 days 
with those that were stored for 15 to 20 days — 
in other words, comparing old red cells with 
older red cells. Other studies have suggested that 
the transfusion of blood from donors who have 
characteristics associated with storage problems 
(so-called bad donors)5 has resulted in poor out-
comes among the recipients, an effect that was 
not analyzed in the current trials. We thus en-
courage the continuation of trials of really fresh 
versus stored red cells and the identification of 
donor characteristics associated with good recipi-
ent outcomes.
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To the Editor: The study by Heddle and col-
leagues is limited in what it actually addresses by 
design, since it specifically shows only that the 
length of red-cell storage is immaterial to mor-
tality in the context of the current practice of 
red-cell transfusion aggregated across diverse 
clinical settings. Given that design, the study 
does not address whether any of the transfusions 
were essential, since most of the patients at high-
est risk were excluded. Therefore, it is uncertain 
whether a between-group difference could have 
been detected. Without knowing whether the 
study design could have detected a true differ-
ence, it remains possible that an important as-
sociation between storage length and outcomes 
exists.
There remains much controversy as to when 
and in which clinical settings transfusions are 
clearly beneficial to mortality,1,2 with wide vari-
ability in transfusion practice3 and, arguably, 
still much overuse. This study leaves unaddressed 
important questions — notably, whether storage 
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